logo

For the Inventor, By the Inventor

Tübingen, Germany

Curevac Se


USPTO Granted Patents = 67


Trademarks = 10

Forward Citations = 143

Loading Chart...
Loading Chart...

59 inventors (with patents filed for the assignee):

goldMedal Benjamin Petsch (30 out of 46 patents)

silverMedal Susanne Rauch (17 out of 22 patents)

bronzeMedal Thomas Kramps (13 out of 26 patents)

4.  Tilmann Roos (10 out of 20 patents)

5.  Margit Schnee (10 out of 21 patents)

6.  Edith Jasny (10 out of 11 patents)

7.  Thomas Schlake (9 out of 33 patents)

8.  Benyamin Yazdan Panah (8 out of 16 patents)

9.  Karl-Josef Kallen (8 out of 29 patents)

10.  Hans Wolfgang Große (8 out of 11 patents)

11.  Mariola Fotin-Mleczek (8 out of 28 patents)

12.  Andreas Thess (7 out of 67 patents)

13.  Daniel Voss (7 out of 12 patents)

14.  Lothar Stitz (5 out of 11 patents)

15.  Jochen Probst (5 out of 37 patents)


Core Competencies:
Nucleic Acid
mRNA Vaccines
Lipid Nanoparticles
CRISPR
Flavivirus Vaccine
Zika Virus Vaccine
RNA Analysis
Respiratory Syncytial Virus
Prostate Cancer
Norovirus Antigen
SARS-CoV-2 Variants
Combination Vaccines

67 patents:

1. 12747451 - RNA encoding an antibody (2026-09-29),
2. 12649914 - METHOD OF RNA IN VITRO TRANSCRIPTION USING A BUFFER CONTAINING A DICARBOXYLIC ACID OR TRICARBOXYLIC ACID OR A SALT THEREOF (2026-06-09),
3. 12618060 - Nucleic acid molecules (2026-05-05),
4. 12589078 - LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS (2026-03-31),
5. 12569549 - Flavivirus vaccine (2026-03-10),
6. 12533422 - MODIFIED RNA WITH DECREASED IMMUNOSTIMULATORY PROPERTIES (2026-01-27),
7. 12527856 - Artificial RNA molecules encoding a norovirus antigen and uses thereof (2026-01-20),
8. 12514918 - Nucleic acid molecules and uses thereof (2026-01-06),
9. 12508308 - Influenza mRNA vaccines (2025-12-30),
10. 12496335 - Zika virus vaccine (2025-12-16),
11. 12492425 - METHODS FOR RNA ANALYSIS (2025-12-09),
12. 12460204 - Artificial nucleic acid molecules for improved protein or peptide expression (2025-11-04),
13. 12447209 - Combination of vaccination and inhibition of the PD-1 pathway (2025-10-21),
14. 12442005 - Artificial nucleic acid molecules for improved protein expression (2025-10-14),
15. 12397048 - Bunyavirales vaccine (2025-08-26),
Company Overview
CureVac SE, based in Tübingen, Germany, is a pioneering biotechnology company specializing in the development of nucleic acid vaccines, particularly mRNA-based therapies. The company focuses on innovative solutions for infectious diseases, including vaccines for flavivirus and Zika virus, as well as advancements in RNA analysis and respiratory syncytial virus treatments. CureVac's core technologies encompass lipid nanoparticles and CRISPR applications, positioning it at the forefront of the rapidly evolving field of mRNA therapeutics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

67 Patents

#5 in Tübingen

#852 in Germany

#11,023 in the World

Tübingen, DE
Tübingen, Germany

Curevac Se

Forward Citations = 143

59 inventors:

goldMedal Benjamin Petsch (30 out of 46 patents)

silverMedal Susanne Rauch (17 out of 22 patents)

bronzeMedal Thomas Kramps (13 out of 26 patents)

4.  Tilmann Roos (10 out of 20 patents)

5.  Margit Schnee (10 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Curevac Se. Retrieved from https://idiyas.com/company/curevac-se

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…